Search

Displaying results 1301 - 1310 of 8412 in total
  1. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  2. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Vayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. … A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study.

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  3. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  4. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    Pipradrol (Meratran) [L2523] was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international

  5. Drug

    Naloxone

    go.drugbank.com/drugs/DB01183
    ApprovedInvestigationalVet approved

    Due to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. … However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal

    Mixtures: TILIDIN 100/8 RETARD 1A PH, TILIDIN 100/8 RETARD 1A PHCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

  7. Drug

    Potassium Iodide

    go.drugbank.com/drugs/DB06715
    ApprovedInvestigational

    SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.

    Mixtures: I D M Expectorant Tab, Virt-Pn
  8. Drug

    DAR-0100A

    go.drugbank.com/drugs/DB16139
    Investigational

    DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).

    Categories: Dopamine D1 Receptor Agonists
  9. Drug

    Aluminum chlorohydrex propylene glycol

    go.drugbank.com/drugs/DB11208
    Approved

    Aluminum chlorohydrex propylene glycol is a complex consisting of Aluminum Chorohydrate and propylene glycol (PG). … It is an antiperspirant active ingredient found in antiperspirant drug products for over-the-counter human use.

  10. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.